1. Report Introduction 2. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (Skin and skin structure infection (SSSI), Skin and soft tissue infection (SSTI)) 2.1. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Disease Overview 2.2. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) History 2.3. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Symptoms 2.4. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Causes 2.5. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Pathophysiology 2.6. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Diagnosis 2.6.1. Diagnostic Guidelines 3. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Current Treatment Patterns 3.1. Treatment Guidelines 4. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) - DelveInsight’s Analytical Perspective 4.1. In-depth Commercial Assessment 4.1.1. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) companies collaborations, Licensing, Acquisition –Deal Value Trends 4.1.1.1. Assessment Summary 4.1.2. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Collaboration Deals 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis 4.1.2.2. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Acquisition Analysis 4.2. Clinical Assessment of Pipeline Drugs 4.2.1. Assessment by Phase of Development 4.2.2. Assessment by Product Type (Mono / Combination) 4.2.2.1. Assessment by Stage and Product Type 4.2.3. Assessment by Route of Administration 4.2.3.1. Assessment by Stage and Route of Administration 4.2.4. Assessment by Molecule Type 4.2.4.1. Assessment by Stage and Molecule Type 4.2.5. Assessment by MOA 4.2.5.1. Assessment by Stage and MOA 5. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Pipeline Therapeutics 5.1. Late Stage Products (Phase-III) 5.1.1. Comparative Analysis 5.2. Mid Stage Products (Phase-II) 5.2.1. Comparative Analysis 5.3. Early Stage Products (Phase-I) 5.3.1. Comparative Analysis 5.4. Pre-clinical and Discovery Stage Products 5.4.1. Comparative Analysis 5.5. Inactive Products 6. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) -Products Analysis 6.1. Product Profiles 6.1.1. Ceftobiprole: Basilea Pharmaceutica 6.1.1.1. Product Description 6.1.1.1.1. Product Overview 6.1.1.1.2. Mechanism of Action 6.1.1.2. Research and Development 6.1.1.2.1. Clinical Studies 6.1.1.2.1.1. Detailed Study Description 6.1.1.2.1.2. Study Results 6.1.1.2.1.3. Clinical Trials: Tabular View 6.1.1.3. Product Development Activities 6.1.1.3.1. Tabulated Product Summary 6.1.1.3.1.1. General Description Table 6.1.2. Iclaprim: Motif Bio 6.1.2.1. Product Description 6.1.2.1.1. Product Overview 6.1.2.1.2. Mechanism of Action 6.1.2.2. Research and Development 6.1.2.2.1. Clinical Studies 6.1.2.2.1.1. Detailed Study Description 6.1.2.2.1.2. Study Results 6.1.2.2.1.3. Clinical Trials: Tabular View 6.1.2.3. Product Development Activities 6.1.2.3.1. Tabulated Product Summary 6.1.2.3.1.1. General Description Table 6.1.3. MRX-I : MicuRx 6.1.3.1. Product Description 6.1.3.1.1. Product Overview 6.1.3.1.2. Mechanism of Action 6.1.3.2. Research and Development 6.1.3.2.1. Clinical Studies 6.1.3.2.1.1. Detailed Study Description 6.1.3.2.1.2. Study Results 6.1.3.2.1.3. Clinical Trials: Tabular View 6.1.3.3. Product Development Activities 6.1.3.3.1. Tabulated Product Summary 6.1.3.3.1.1. General Description Table To be continued in the report………………………… 7. Recent Technologies 8. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Key Companies 8.1. Motif Bio 8.2. Debiopharm 8.3. Arrevus 8.4. GlaxoSmithKline 8.5. MicuRx Pharmaceuticals 8.6. Wockhardt 8.7. Innovation Pharmaceuticals 9. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Key Products 9.1. Iclaprim 9.2. Afabicin 9.3. Fusidic acid oral 9.4. Gepotidacin 9.5. Contezolid 9.6. Levonadifloxacin 9.7. Alalevonadifloxacin 9.8. Brilacidin 10. Dormant and Discontinued Products 10.1. Dormant Products 10.1.1. Reasons for being dormant 10.2. Discontinued Products 10.2.1. Reasons for the discontinuation 11. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) - Unmet Needs 12. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) - Future Perspectives 13. Appendix 14. Report Methodology 14.1. Secondary Research 14.2. Expert Panel Validation

TABLE 1 Diagnostic Guidelines TABLE 2 Treatment Guidelines TABLE 3 Assessment Summary TABLE 4 Company-Company Collaborations (Licensing / Partnering) Analysis TABLE 5 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Acquisition Analysis TABLE 6 Assessment by Phase of Development TABLE 7 Assessment by Product Type (Mono / Combination) TABLE 8 Assessment by Stage and Product Type TABLE 9 Assessment by Route of Administration TABLE 10 Assessment by Stage and Route of Administration TABLE 11 Assessment by Molecule Type TABLE 12 Assessment by Stage and Molecule Type TABLE 13 Assessment by MOA TABLE 14 Assessment by Stage and MOA TABLE 15 Late Stage Products (Phase-III) TABLE 16 Mid Stage Products (Phase-II) TABLE 17 Early Stage Products (Phase-I) TABLE 18 Pre-clinical and Discovery Stage Products TABLE 19 Inactive Products TABLE 20 Dormant Products TABLE 21 Discontinued Products Figure 1 Disease Overview Figure 1 History Figure 2 Symptoms Figure 3 Causes Figure 4 Pathophysiology Figure 5 Diagnostic Guidelines Figure 6 Treatment Guidelines Figure 7 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) companies collaborations, Licensing, Acquisition –Deal Value Trends Figure 8 Company-Company Collaborations (Licensing / Partnering) Analysis Figure 9 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Acquisition Analysis Figure 10 Assessment by Phase of Development Figure 11 Assessment by Product Type (Mono / Combination) Figure 12 Assessment by Stage and Product Type Figure 13 Assessment by Route of Administration Figure 14 Assessment by Stage and Route of Administration Figure 15 Assessment by Molecule Type Figure 16 Assessment by Stage and Molecule Type Figure 17 Assessment by MOA Figure 18 Assessment by Stage and MOA Figure 19 Late Stage Products (Phase-III) Figure 20 Mid Stage Products (Phase-II) Figure 21 Early Stage Products (Phase-I) Figure 22 Pre-clinical and Discovery Stage Products Figure 23 Inactive Products Figure 24 Dormant Products Figure 25 Discontinued Products Figure 26 Unmet Needs

Motif Bio Debiopharm Arrevus GlaxoSmithKline MicuRx Pharmaceuticals Wockhardt Melinta Therapeutics Merck & Co Durata Therapeutics Paratek Pharmaceuticals Innovation Pharmaceuticals